Active Ingredient History

  • Now
Arbaclofen placarbil is a prodrug of R-baclofen. Arbaclofen placarbil possesses more favorable pharmacokinetic profile than baclofen, with less fluctuations in plasma drug levels. It was being developed as a potential treatment for patients with GERD and spasticity due to multiple sclerosis; however, in May 2013 XenoPort announced the termination of development because of unsuccessful results in phase III clinical trials.   Wikipedia

  • SMILES: CC(C)[C@H](OC(=O)NC[C@H](CC(=O)O)c1ccc(Cl)cc1)OC(=O)C(C)C
  • Mol. Mass: 399.87
  • ALogP: 3.81
  • ChEMBL Molecules:
More Chemistry
4-chloro-beta-((((2-methyl-1-(2-methyl-1-oxopropoxy)propoxy)carbonyl)amino)methyl)benzenepropanoic acid | arbaclofen | arbaclofen hydrochloride | arbaclofen placarbil | (r)-4-amino-3-(4-chlorophenyl)butan­oic acid | (r)-baclofen | stx209 | xp19986 | xp-19986


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue